Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Equity Average (2021 - 2025)

Historic Equity Average for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$1.4 million.

  • Lyra Therapeutics' Equity Average fell 10524.46% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year decrease of 10524.46%. This contributed to the annual value of $50.5 million for FY2024, which is 4064.08% down from last year.
  • Lyra Therapeutics' Equity Average amounted to -$1.4 million in Q3 2025, which was down 10524.46% from $2.7 million recorded in Q2 2025.
  • Lyra Therapeutics' Equity Average's 5-year high stood at $99.7 million during Q3 2022, with a 5-year trough of -$1.4 million in Q3 2025.
  • For the 5-year period, Lyra Therapeutics' Equity Average averaged around $53.3 million, with its median value being $58.4 million (2021).
  • Its Equity Average has fluctuated over the past 5 years, first surged by 15505.88% in 2023, then crashed by 10524.46% in 2025.
  • Quarter analysis of 5 years shows Lyra Therapeutics' Equity Average stood at $40.8 million in 2021, then surged by 113.46% to $87.0 million in 2022, then decreased by 0.18% to $86.8 million in 2023, then tumbled by 81.45% to $16.1 million in 2024, then crashed by 108.4% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q3 2025, $2.7 million for Q2 2025, and $7.7 million during Q1 2025.